PFA
ABBV icon

Pathway Financial Advisers’s AbbVie ABBV Stock Holding History

Pathway Financial Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7M Buy
34,586
+349
+1% +$75.1K 2.19% 6
2026
Q1 		$7.45M Buy
34,237
+686
+2% +$152K 2.11% 6
2025
Q4 		$7.67M Sell
33,551
-25
-0.1% -$5.7K 2.22% 5
2025
Q3 		$7.73M Buy
33,576
+1,082
+3% +$220K 2.26% 4
2025
Q2 		$6.03M Buy
32,494
+379
+1% +$70.4K 1.95% 7
2025
Q1 		$6.73M Sell
32,115
-601
-2% -$117K 2.31% 4
2024
Q4 		$5.81M Buy
32,716
+37
+0.1% +$6.8K 1.95% 7
2024
Q3 		$6.45M Sell
32,679
-238
-0.7% -$44.4K 2.92% 2
2024
Q2 		$5.62M Buy
32,917
+520
+2% +$86.1K 2.01% 7
2024
Q1 		$5.9M Sell
32,397
-1,710
-5% -$295K 2.12% 6
2023
Q4 		$5.29M Buy
34,107
+17
+0% +$2.48K 2.01% 7
2023
Q3 		$5.08M Buy
+34,090
New +$5M 2.1% 6
2023
Q1 		$5.42M Sell
34,019
-4,126
-11% -$631K 2.18% 4
2022
Q4 		$6.16M Buy
+38,145
New +$5.85M 2.5% 1

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pathway Financial Advisers's ABBV Position: Q2 2026 in Review

Pathway Financial Advisers increased its AbbVie (ABBV) stake by 1% in Q2 2026, buying an estimated $75.1K and bringing the position to 34,586 shares worth $8.7M. The position accounts for 2.19% of the portfolio, ranked #6.

Pathway Financial Advisers first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Pathway Financial Advisers held 34,586 shares of AbbVie worth $8.7M as of Q2 2026.
  • Pathway Financial Advisers bought 349 AbbVie shares in Q2 2026, an estimated $75.1K.
  • AbbVie made up 2.19% of Pathway Financial Advisers's portfolio in Q2 2026, its #6 holding.
  • Pathway Financial Advisers first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • 4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pathway Financial Advisers's 13F filing for Q2 2026, filed 30 Jul 2026.